{"article":{"annotation":{"article_id":"uk-mhra-casgevy-gene-editing-children-approval-2026","available_at":"2026-10-31T22:01:35.243807Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"73e5787d01f79339b1ec7ad665d4938e2c3538a559a574d0072d8ad4295b74e2","input_sha256":"8c3799cf62f8e1726fae6b905be37be706533b0df1ef6368542181fcb4b77d71","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"GB","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"]}],"geometry":null,"id":"iso3166-1:GB","kind":"country-or-area","labels":{"ar":"المملكة المتحدة لبريطانيا العظمى وآيرلندا الشمالية","en":"United Kingdom of Great Britain and Northern Ireland","es":"Reino Unido de Gran Bretaña e Irlanda del Norte","fr":"Royaume-Uni de Grande-Bretagne et d’Irlande du Nord"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: Healthcare, disease","source_urls":["https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"]}],"method":"controlled-rules-v1","rule_id":"health","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=de","category":"health","content":{"key_points":[],"paragraphs":["Die britische Aufsichtsbehörde MHRA hat am 29. Oktober die Marktzulassung für die Gen-Editing-Behandlung Casgevy auf Kinder ab fünf Jahren mit schwerer Sichelzellkrankheit und transfusionsabhängiger Beta-Thalassämie ausgeweitet.","Casgevy (Exagamglogen-Autotemcel) war bislang auf Patienten ab zwölf Jahren beschränkt. Die Zelltherapie nutzt die Genschere CRISPR, um blutbildende Stammzellen des Patienten im Labor so zu modifizieren, dass wieder fetales Hämoglobin produziert wird, bevor sie nach einer Konditionierung reinfundiert werden.","Die MHRA begründete die Zulassungserweiterung mit klinischen Daten, die eine signifikante Senkung von vasookklusiven Schmerzkrisen und Transfusionsbedarfen bei jüngeren Kindern belegen. Die Behandlung bleibt spezialisierten Zentren mit strenger Überwachung von Infektionsrisiken und Zytopenien vorbehalten."],"sections":[]},"corrections":[],"country":"GB","data":{"blocks":[{"description":{"ar":"نشر إعلان توسيع الموافقة الرسمي في 29 أكتوبر 2026.","de":"Veröffentlichung der offiziellen Mitteilung zur Zulassungserweiterung am 29. Oktober 2026.","en":"Publication of the official approval extension announcement on 29 October 2026.","es":"Publicación del comunicado oficial de ampliación de autorización el 29 de octubre de 2026.","fr":"Publication du communiqué officiel d'élargissement de l'autorisation le 29 octobre 2026.","pt":"Publicação do anúncio oficial de alargamento da autorização em 29 de outubro de 2026.","tr":"29 Ekim 2026’da resmî onay genişletme duyurusunun yayımlanması."},"id":"source-announcement","items":[{"date":"2026-10-29","description":{"ar":"تم منح التوسيع التنظيمي في 29 أكتوبر 2026 لمرضى الأطفال المصابين بالأنيميا المنجلية وبيتا ثلاسيميا.","de":"Regulatorische Erweiterung am 29. Oktober 2026 für pädiatrische Patienten erteilt.","en":"Regulatory extension granted on 29 October 2026 for pediatric sickle-cell and beta-thalassaemia patients.","es":"Ampliación regulatoria concedida el 29 de octubre de 2026 para pacientes pediátricos falciformes y con talasemia.","fr":"Extension réglementaire accordée le 29 octobre 2026 pour les patients pédiatriques atteints de drépanocytose et thalassémie.","pt":"Extensão regulamentar concedida em 29 de outubro de 2026 para doentes pediátricos com drepanocitose e talassemia.","tr":"Pediatrik orak hücre ve beta talasemi hastaları için 29 Ekim 2026'da mevzuat genişletmesi yapıldı."},"label":{"ar":"وكالة MHRA توسع ترخيص كاسجيفي ليشمل الأطفال من سن 5 سنوات فما فوق","de":"MHRA erweitert Casgevy-Alterszulassung auf Kinder ab 5 Jahren","en":"MHRA expands Casgevy age authorisation to children aged 5 and over","es":"La MHRA amplía la autorización de Casgevy a niños a partir de 5 años","fr":"La MHRA élargit l'autorisation de Casgevy aux enfants de 5 ans et plus","pt":"MHRA alarga autorização do Casgevy a crianças a partir dos 5 anos","tr":"MHRA, Casgevy yaş yetkisini 5 yaş ve üzerine genişletti"},"status":"occurred"}],"methodology":{"ar":"يسجل التاريخ يوم نشر المصدر الأولي المشار إليه. ويحدد النطاق التنظيمي وفئات الأعمار في المادة.","de":"Das Datum bezeichnet die Veröffentlichung der angeführten Primärquelle. Regulatorischer Geltungsbereich und Altersgrenzen werden im Artikel dargelegt.","en":"The date records publication of the cited primary source. Regulatory scope and age indications are stated in the article.","es":"La fecha registra la publicación de la fuente primaria citada. El alcance regulatorio y las indicaciones de edad se detallan en el artículo.","fr":"La date correspond à la publication de la source primaire citée. Le périmètre réglementaire et les indications d'âge sont précisés dans l'article.","pt":"A data regista a publicação da fonte primária citada. O âmbito regulamentar e os escalões etários são detalhados no artigo.","tr":"Tarih, atıf yapılan birincil kaynağın yayımlandığı günü gösterir. Düzenleyici kapsam ve yaş endikasyonları haberde belirtilmiştir."},"sourceUrls":["https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"],"title":{"ar":"نشر المصدر","de":"Quellenveröffentlichung","en":"Source publication","es":"Publicación de la fuente","fr":"Publication de la source","pt":"Publicação da fonte","tr":"Kaynak yayını"},"type":"events","updatedAt":"2026-11-01T00:43:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026/data/source-announcement?lang=de&format=csv","json":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026/data/source-announcement?lang=de&format=json"},"id":"source-announcement"}],"data_types":["events"],"editorial_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-3de095f4-3470-5d3b-a037-614eb4c44b2f","event_period":"2026-10-29","event_period_basis":"event-or-reference-period","id":"uk-mhra-casgevy-gene-editing-children-approval-2026","image":null,"importance":0.6,"language":"de","modified_at":"2026-11-01T00:43:00Z","publication_basis":"publication-record","published_at":"2026-10-31T22:01:30+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"uk-mhra-casgevy-gene-editing-children-approval-2026","sources":[{"checkedAt":"2026-11-01","name":"Medicines and Healthcare products Regulatory Agency, United Kingdom","publishedAt":"2026-10-29","url":"https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"}],"summary":"Die britische Aufsichtsbehörde MHRA hat am 29. Oktober die Marktzulassung für die Gen-Editing-Behandlung Casgevy auf Kinder ab fünf Jahren mit schwerer Sichelzellkrankheit und transfusionsabhängiger Beta-Thalassämie ausgeweitet.","text":"Die britische Aufsichtsbehörde MHRA hat am 29. Oktober die Marktzulassung für die Gen-Editing-Behandlung Casgevy auf Kinder ab fünf Jahren mit schwerer Sichelzellkrankheit und transfusionsabhängiger Beta-Thalassämie ausgeweitet.\n\nDie britische Aufsichtsbehörde MHRA hat am 29. Oktober die Marktzulassung für die Gen-Editing-Behandlung Casgevy auf Kinder ab fünf Jahren mit schwerer Sichelzellkrankheit und transfusionsabhängiger Beta-Thalassämie ausgeweitet.\n\nCasgevy (Exagamglogen-Autotemcel) war bislang auf Patienten ab zwölf Jahren beschränkt. Die Zelltherapie nutzt die Genschere CRISPR, um blutbildende Stammzellen des Patienten im Labor so zu modifizieren, dass wieder fetales Hämoglobin produziert wird, bevor sie nach einer Konditionierung reinfundiert werden.\n\nDie MHRA begründete die Zulassungserweiterung mit klinischen Daten, die eine signifikante Senkung von vasookklusiven Schmerzkrisen und Transfusionsbedarfen bei jüngeren Kindern belegen. Die Behandlung bleibt spezialisierten Zentren mit strenger Überwachung von Infektionsrisiken und Zytopenien vorbehalten.","title":"Britische MHRA weitet Zulassung der CRISPR-Therapie Casgevy auf Kinder ab fünf Jahren aus","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/uk-mhra-casgevy-gene-editing-children-approval-2026"}],"url":"https://newsverum.com/de/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},"version":"1"}
